Table 1.

Baseline characteristics of the patients by chemotherapy cohort

Characteristic by cohort	Palo plus 1-day Dex		Palo plus 3-day Dex		P valuea
	N	%	N	%
MEC, evaluable patients	125	100	112	100
Age (years)
Median (min–max)	59 (31–77)		60 (35–80)
<50 years	27	21.6	24	21.4	1.0
Gender					0.515
Male	63	50.4	51	45.5
Female	62	49.6	61	54.5
Early stage disease	61	48.8	65	58.0	0.192
Primary tumor					0.792
Breast	28	22.4	31	27.7
Colorectal	66	52.8	53	47.3
Lung	15	12.0	13	11.6
Other	16	12.8	15	13.4
Chemotherapy regimen					0.840
Oxaliplatin-based	63	50.4	52	46.4
Carboplatin-based	20	16.0	16	14.3
Irinotecan-based	14	11.2	15	13.4
Otherb	28	22.4	29	25.9
Alcohol consumption					0.604
Never	67	53.6	56	50.0
Everyday	58	46.4	56	50.0
Risk group					0.841
Lowc	111	88.8	98	87.5
Highd	14	11.2	14	12.5
AC, evaluable patients	186	100	194	100
Age (years)
Median (min–max)	51 (28–77)		50 (26–78)
<50 years	81	43.5	93	47.9	0.411
Early-stage breast cancer	186	100	194	100
Alcohol consumption					0.559
Never/Occasionallye	174	93.5	178	91.7
Everyday	12	6.5	16	8.3
Risk group					0.257
Lowc	138	74.2	133	68.6
Highd	48	25.8	61	31.4

Palo palonosetron, Dex dexamethasone, MEC moderately emetogenic chemotherapy, AC anthracycline (doxorubicin or epirubicin) plus cyclophosphamide

^aFisher’s exact test or chi-square test (two-tailed)

^bPatients undergoing anthracycline or cyclophosphamide-containing chemotherapy

^cLow-risk patients were free from both vomiting and moderate-to-severe nausea in the acute phase

^dHigh-risk patients experienced vomiting or moderate-to-severe nausea in the acute phase

^eIncluding 53 patients with missing data for alcohol consumption